Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AT
aTyr Pharma, Inc. Common Stock
ATYR
Mkt Cap
$17.5M
Volume
1.69M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AT
ATYR
AT
aTyr Pharma, Inc. Common Stock
ATYR
News
·
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
Mkt Cap
$18.0M
Volume
1.69M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma announced it will advance efzofitimod development in pulmonary sarcoidosis following a Type C FDA meeting. The company plans to submit an IND in June 2026 for a Phase 3 study using FVC as primary endpoint and KSQ-Lung as secondary endpoint. The company ended Q1 2026 with $68.3 million in cash and is on track to complete enrollment in its Phase 2 SSc-ILD study in H1 2026.
GlobeNewswire Inc. · May 15, 2026
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight
The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.
GlobeNewswire Inc. · Apr 8, 2026
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
Hagens Berman is pursuing a securities class action lawsuit against aTyr Pharma after its flagship drug trial failed, causing an 83% stock price collapse. The lawsuit alleges the company misrepresented the efficacy of its drug Efzofitimod and concealed material adverse facts about its performance.
GlobeNewswire Inc. · Dec 6, 2025
ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights
A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod, with investors having until December 8, 2025 to apply as lead plaintiff.
GlobeNewswire Inc. · Dec 6, 2025
מועד אחרון לתביעה נגד ATYR: רוזן, משרד עורכי דין מוערך בעולם, מעודדים את משקיעי ATyr Pharma, Inc עם הפסדים של מעל מאה אלף דולר, להשיג ייעוץ לפני המועד החשוב של 8 בדצמבר בתביעה ייצוגית בניירות ערך - ATYR
Rosen Law Firm alerts ATyr Pharma investors about a securities class action lawsuit deadline on December 8, 2025, related to allegedly misleading statements about the effectiveness of the drug Efzofitimod.
GlobeNewswire Inc. · Dec 6, 2025
ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages aTyr Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action - ATYR
Rosen Law Firm is pursuing a securities class action against aTyr Pharma for allegedly providing false and misleading statements about the efficacy of their drug Efzofitimod during the period of January 16, 2025 to September 12, 2025.
GlobeNewswire Inc. · Dec 5, 2025
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod during the period of January 16-September 12, 2025.
GlobeNewswire Inc. · Dec 5, 2025
Holzer & Holzer, LLC Reminds Investors of Upcoming December 8, 2025 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Marex, Inc. (MRX), aTyr Pharma, Inc. (ATYR), WPP plc (WPP) , and Cepton, Inc. (CPTN)
Law firm Holzer & Holzer reminds investors of upcoming December 8, 2025 lead plaintiff deadlines for shareholder class action lawsuits against multiple companies, alleging false statements and potential financial misconduct.
GlobeNewswire Inc. · Dec 5, 2025
DEADLINE ALERT for ATYR, MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions
Law firm alerts shareholders about potential securities fraud class action lawsuits for multiple companies, citing misleading statements and undisclosed information during specific class periods.
GlobeNewswire Inc. · Dec 3, 2025
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi is investigating potential securities claims against aTyr Pharma after the company's stock dropped 83.25% following disappointing clinical trial results for its drug Efzofitimod, which failed to demonstrate significant steroid reduction in patients.
GlobeNewswire Inc. · Nov 29, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AT
ATYR
aTyr Pharma, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ATYR
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ATYR yet.
Related Tickers
Earnings